Medication Overuse Headache (MOH) was previously termed analgesic rebound headache, drug-induced headache, and medication-misuse headache. It is not a primary headache but frequently coexists with primary chronic daily headache. 
Background
Some migraine patients fall into a trap by overusing the medications they take when they get their headaches, ending in a downward spiral of daily or near-daily headaches for which their medications become less and less effective. This condition is called medication overuse headache. It has also been termed analgesic rebound headache, drug-induced headache, and medication-misuse headache. Although not a primary type of chronic daily headache, MOH deserves proper coverage since it frequently coexists with primary headache. 1, 2 After successful MOH treatment, preventive medication for the underlying primary disorder have a greater chance for success. 3 Pathophysiology Available evidence suggests all drugs used for the acute symptomatic treatment of headache can cause MOH in primary headache disorders. 4, 5, 6 The precise mechanisms that lead to MOH are still uncertain.
Genetic predisposition
Various studies and clinical observations suggest that MOH is restricted to individuals who already have other headache disorders 4 . Furthermore, MOH does not develop de novo in individuals with no previous headache history. 5 In a study of 103 patients using daily analgesics for arthritic pain but not for headache, only eight patients (7.6 percent) had chronic daily headache, each of whom reported a previous history of episodic migraine. 6 Patients with migraine and tension-type headache seem to have the highest potential for MOH. 7 However, MOH has also been described in cluster headache 8 and in hemicrania continua. 9 
Central sensitization
Investigations demonstrating facilitation of trigeminal pain processing in patients with chronic headache have suggested that central sensitization, the same process that occurs in migraine, could lead to MOH. 7, 10 In humans, chronic exposure to triptans and other analgesics could lead to down regulation of serotonin receptors. 4, 11, 12 Biobehavioral factors It has been proposed that MOH is a biobehavioral disorder. 13 Some patients may have addictive disease, . characterized by compulsive drug seeking and drug taking behavior despite negative consequences, other patients may use opiates or other drugs with sedative/ anxiolytic effects to treat both pain and a coexistent anxiety disorder. 13 In a prospective population-based longitudinal study of 32,067 adults from Norway, subjects using analgesics daily or weekly at baseline had a significantly increased risk of chronic pain 11 years later compared to those who never used analgesics. 14 
Epidemiology
The prevalence of MOH in the general population is approximately 1 percent, 15 and is higher in women than in men. 10, 19 In a population-based study of over 49,000 subjects from Norway, the prevalence of chronic headache with analgesic overuse lasting three months or longer was 0.9 percent overall 20 In two smaller population studies from Spain, the prevalence of medication overuse headache was approximately 1.5 percent, 18, 21 with a female to male ratio of 17:1. 21 Among patients who are seen at specialized headache centers, the prevalence of MOH is much higher, ranging from 4 to 80 percent. 4, 22, 23 Causal medications All acute symptomatic medications used to treat headaches have the potential for causing MOH. 4, 5, 6 Based upon the literature and clinical experience, the risk appears to be highest with opioids, butalbital (Barbiturate with an intermediate duration of action)-containing combination analgesics, and aspirin/ acetaminophen/caffeine combinations. 10, 24 The evidence supporting these risks is illustrated by the following reports: A 2008 review of clinic-based and population studies found that, for opiates, the increased risk was more pronounced in men, and the critical dose of exposure was approximately eight days a month. 25, 26 In a 2004 report from a tertiary headache center in New York of 169 patients who were followed in the last five years of the study (i.e., the triptan era), the drugs most often associated with MOH included the following ( Figure:1) . 27 In a 2002 prospective German study of 98 patients with MOH, including 70 patients with migraine as the underlying primary headache type, overuse of triptans led to MOH sooner than overuse of ergots or analgesics, and did so at a lower frequency of use. 28 The mean interval until onset of MOH was shortest for triptans (1.7 years), longer for ergots (2.7 years), and longest for analgesics (codeine, barbiturates, caffeine combinations) (4.8 years). 28 The frequency of use for drugs implicated in MOH varies from country to country and is influenced by multiple factors. 4 Butalbital is commonly overused in the United States, while simple analgesics and caffeine-containing drugs are most commonly associated with MOH in other parts of the world (eg, Spain and Brazil). 18, 29 Until the mid 1990s, combination analgesics with codeine or caffeine, or ergots combined with caffeine were the most frequently overused drugs associated with MOH in many European countries. 30 With the introduction of triptans, the pattern of MOH may be changing. In a review of patients seen at a single headache center in the US from 1990 to 2005, MOH secondary to ergotamine decreased while MOH secondary to triptans increased. 31 It is often difficult to identify a single causal substance for MOH, since many patients are overusing more than one drug. 4, 27 
Clinical features
The development of MOH is typically preceded by an episodic headache disorder, typically migraine or tension-type headache, that has been treated with frequent and excessive amounts of acute symptomatic medications. 10 In clinical practice, MOH often manifests as a headache that is present or develops upon awakening. 10 The severity, location and type of head pain can vary significantly among different individuals, but headache commonly occurs daily or nearly daily. 10 Nausea, asthenia, difficulty concentrating, memory problems and irritability can accompany. 10 To some extent, the clinical features may depend upon the type of headache medication that is overused. 32
Diagnosis
The diagnosis is based upon clinical impression. A history of analgesic use averaging more than two to three days per week in association with chronic daily headache supports the diagnosis. The diagnosis is made when there is a pattern of frequent headaches that fulfill diagnostic criteria for MOH.
Diagnostic criteria
The International Classification of Headache Disorders 2nd edition (ICHD 2) diagnostic criteria for MOH were published in 2004 33 and revised in 2006. 34 The revised criteria are as follows ( Table-I) .
Table-I
The revised diagnostic criteria for MOH 33 A. Headache present on >15 days a month B. Regular overuse for more than three months of one or more acute/symptomatic treatment drugs:
1 Ergotamine, triptans, opioids, or combination analgesic medications on >10 days a month on a regular basis for more than three months 2 Simple analgesics or any combination of ergotamine, triptans, analgesic opioids on >15 days a month on a regular basis for more than three months without overuse of any single class alone C Headache has developed or markedly worsened during medication overuse
Note that "overuse" is defined by the frequency of medication treatment, and the criteria for overuse are specific for the type of medication being overused 10 .
Differential diagnosis:
Any form of chronic daily headache, whether primary or secondary, needs to be considered in the differential diagnosis. A high frequency of drug intake does not mean that MOH is the only headache disorder that is present. 4 Typically, the patient has an underlying primary headache disorder.
Treatment
Withdrawal of the overused medication as soon as possible is the treatment of choice. 35 Withdrawal of overused acute medications can be accomplished on an outpatient or inpatient basis. 36 MOH treatment involves four steps (Table-II Table-III) . Table- In every patient with rebound, physicians should address the wean up front in the first steps taken. Prevention and wean should be added at the same time.
There are four levels of wean (Table-IV) . 
